• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Recent Advances in the Study of N-(4-Aminophenyl)butanamide (CAS: 116884-02-7) in Chemical Biology and Pharmaceutical Research

N-(4-Aminophenyl)butanamide (CAS: 116884-02-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications and unique chemical properties. This compound, characterized by its amide linkage and aromatic amine group, has been the subject of multiple studies aimed at elucidating its biological activity, pharmacokinetics, and potential as a drug candidate. The following sections provide a comprehensive overview of the latest research findings related to this compound, highlighting its significance in modern drug discovery and development.

Recent studies have focused on the synthesis and optimization of N-(4-Aminophenyl)butanamide to enhance its bioavailability and therapeutic efficacy. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that structural modifications of the compound, particularly at the butanamide moiety, could significantly improve its binding affinity to target proteins involved in inflammatory pathways. These findings suggest that N-(4-Aminophenyl)butanamide derivatives may serve as promising candidates for the development of novel anti-inflammatory agents.

In addition to its anti-inflammatory potential, N-(4-Aminophenyl)butanamide has also been investigated for its role in cancer therapy. A preclinical study conducted by researchers at the National Cancer Institute revealed that the compound exhibits selective cytotoxicity against certain cancer cell lines, particularly those associated with breast and prostate cancers. Mechanistic studies indicated that the compound induces apoptosis via the mitochondrial pathway, making it a potential candidate for targeted cancer therapies. Further research is underway to explore its synergistic effects with existing chemotherapeutic agents.

The pharmacokinetic profile of N-(4-Aminophenyl)butanamide has also been a focal point of recent research. A 2024 publication in Drug Metabolism and Disposition reported that the compound demonstrates favorable absorption and distribution characteristics in rodent models, with a half-life sufficient for once-daily dosing. However, challenges related to its metabolism and elimination pathways were noted, prompting ongoing investigations into prodrug strategies and formulation optimizations to address these limitations.

Beyond its therapeutic applications, N-(4-Aminophenyl)butanamide has been utilized as a key intermediate in the synthesis of more complex pharmaceutical compounds. Its versatility as a building block in organic synthesis has been highlighted in several recent patents, underscoring its value in the pharmaceutical industry. For instance, a 2023 patent application described its use in the production of novel kinase inhibitors, further expanding its potential applications in drug development.

In conclusion, the growing body of research on N-(4-Aminophenyl)butanamide (CAS: 116884-02-7) underscores its multifaceted role in chemical biology and pharmaceutical sciences. From its promising therapeutic properties to its utility as a synthetic intermediate, this compound continues to be a subject of intense scientific inquiry. Future studies are expected to further elucidate its mechanisms of action and optimize its pharmacological profile, paving the way for its potential clinical translation.

• 1129-50-6(Butanamide, N-phenyl-)
• 651767-94-1(Octanamide, 8-amino-N-phenyl-)
• 15473-32-2(Decanamide, N-phenyl-)
• 56051-98-0(Heptanamide, N-phenyl-)
• 6833-04-1(Heptanediamide, N,N'-diphenyl-)
• 26179-35-1(Hexanediamide,N1,N6-bis(4-aminophenyl)-)
• 16099-54-0(Octadecanamide,N,N'-1,4-phenylenebis-)
• 15510-09-5(Butanediamide,N1,N4-diphenyl-)
• 10264-18-3(N-phenylpentanamide)
• 62393-56-0(Pentanamide, N,N'-1,4-phenylenebis-)